Marino Garcia serves as the President and Chief Executive Officer at Dianthus Therapeutics Inc., a biopharmaceutical company focused on developing novel therapies for autoimmune and inflammatory diseases. With an extensive background in the biopharmaceutical industry, Garcia has been instrumental in leading Dianthus Therapeutics through various stages of growth and development. His strategic vision and leadership have been pivotal in advancing the company's mission to bring innovative treatments to patients in need. Prior to joining Dianthus Therapeutics, Garcia held several senior leadership positions at prominent biopharmaceutical companies. He has a proven track record of successfully guiding organizations through complex drug development processes, from early-stage research to commercialization. One of his notable achievements includes overseeing the development and launch of a groundbreaking therapy that significantly improved patient outcomes in the autoimmune disease space. Garcia's expertise in drug development, coupled with his strong business acumen, has positioned him as a respected leader in the industry. As President and CEO of Dianthus Therapeutics, Garcia is responsible for setting the company's overall strategic direction and ensuring the successful execution of its clinical programs. Under his leadership, the company has made significant strides in advancing its pipeline of novel therapies, with several promising candidates currently in various stages of clinical trials. Garcia's commitment to innovation and patient-centric care continues to drive Dianthus Therapeutics forward, as the company strives to make a meaningful impact on the lives of patients with autoimmune and inflammatory diseases.